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BACKGROUND: The community-based incidence of cancer treatment-related long-term consequences is uncertain. We sought to
establish the burden of health outcomes that have been associated with treatment among British long-term cancer survivors.
METHODS: We identified 26213 adults from the General Practice Research Database who have survived 5 years or more following
breast, colorectal or prostate cancer. Four age-, sex- and general practice-matched non-cancer controls were selected for each
survivor. We considered the incidence of treatment-associated health outcomes using Cox proportional hazards models.
RESULTS: Breast cancer survivors had an elevated incidence of heart failure (hazards ratio (HR) 1.95, 95% confidence interval (CI)
1.27–3.01), coronary artery disease (HR 1.27, 95% CI 1.11–1.44), hypothyroidism (HR 1.26, 95% CI 1.02–1.56) and osteoporosis
(HR 1.26, 95% CI 1.13–1.40). Among colorectal cancer survivors, there was increased incidence of dementia (HR 1.68, 95% CI
1.20–2.35), diabetes (HR 1.39, 95% CI 1.12–1.72) and osteoporosis (HR 1.41, 95% CI 1.15–1.73). Prostate cancer survivors had the
highest risk of osteoporosis (HR 2.49, 95% CI 1.93–3.22).
CONCLUSIONS: The study confirms the occurrence of increased incidence of chronic illnesses in long-term cancer survivors attributable
to underlying lifestyle and/or cancer treatments. Although the absolute risk of the majority of late effects in the cancer survivors
cohort is low, identifying prior risk of osteoporosis by bone mineral density scanning for prostate survivors should be considered.
There is an urgent need to improve primary care recording of cancer treatment.
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More than 50% of adults with cancer in the UK will survive for at
least 5 years following their initial diagnosis (Cancer Research UK,
2006). Recent improvements in cancer survival are largely due to
earlier diagnosis and advancements in treatment. Despite having
favourable effects on cancer survival, radiotherapy, hormone
treatment and combination chemotherapy regimens can cause
long-term organ damage and functional disabilities. These
long-term toxicities, or late effects, defined as ‘unrecognised
toxicities that are absent or subclinical at the end of therapy’ can
manifest as new diagnoses months to years after the completion
of primary cancer treatment (Hewitt et al, 2006). Late effects
related to treatment are widely variable and are linked to
characteristics of the cancer, the modality and intensity of
treatment and the underlying health status of the individual
experiencing cancer.
Some late effects are predictable, for example, the effect of
radiotherapy treatment on adjacent organs. This may result in the
increased incidence of hypothyroidism and heart failure in breast
cancer patients (Clarke et al, 2005; Darby et al, 2005; Smith et al,
2008). The effects of hormonal treatments are also predictable;
changes in bone physiology and increases in osteoporosis are
increasingly found in patients treated with hormone therapy (Chen
et al, 2005; Lopez et al, 2005; Shahinian et al, 2005; Saad et al,
2008; Brown et al, 2010). The late effects of chemotherapy are less
easy to predict and are often drug specific. For example, cognitive
impairment is a well-recognised late effect of chemotherapy
(Hewitt et al, 2006). A conceptual framework of its aetiology
proposes interactions between treatment effects on clotting in
small blood vessels and endogenous hormones, in addition to
chemotherapy mediating depression and fatigue through cytokine
involvement leading to cognitive impairment (Heflin et al, 2005).
Finally, some associations are difficult to explain with current
knowledge. There is a reported association between diabetes
mellitus and colorectal cancer: both diseases share common risk
factors, but diabetes has also been shown to be a potential
independent risk factor of several common cancers including
colorectal cancer (Larsson et al, 2005). In addition to the effects of
treatment, cancer patients are also at increased risk of developing
subsequent disease because of the risk factors that led to the
original cancer. Some of these risk factors are modifiable, for
example, smoking and alcohol, and a cancer diagnosis may
provide motivation for lifestyle change. Other factors, such as
genetic mutations and polymorphisms, are currently immutable.
A summary of common long-term and late effects of treatments
for breast, colorectal and prostate cancer is shown in Table 1.
The prevalence of these late effects in a general population of
adult cancer survivors is still uncertain; however, it is likely that
with sophisticated and intense treatments long-term effects will
become more common (Carver et al, 2007). The complicated *Correspondence: Dr NF Khan; E-mail: nada.khan@phc.ox.ac.uk
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that community-based prevalence is difficult to predict. It is
important to determine the burden of late effects in cancer
survivors in order to provide guidance on long-term monitoring,
case finding for disease, health promotion and planning service
provision.
The main aim of the research reported here was to assess
the size of this problem by documenting the incidence of late
effects related to cancer treatment in a population-based cohort of
cancer survivors in the UK. Our data, which were derived from
comprehensive primary care records, also allowed us to explore
the relative incidence of all health problems in cancer survivors
compared with a control population.
MATERIALS AND METHODS
The source of data and participants
This paper reports a matched cohort analysis of longitudinal
primary care records of cancer survivors and controls from the
UK General Practice Research Database (GPRD) (Walley and
Mantgani, 1997). The GPRD includes data on individual-level
clinical diagnoses, test results, prescriptions, referrals and
significant morbidity events in the patients’ medical history
(MHRA, 2004). All survivors of breast, colorectal and prostate
cancer with more than 5 years follow-up post diagnosis were
identified from the GPRD and matched to four control patients on
the basis of age (within 1 year), gender and primary care practice.
These matched groups were followed from the start of a 3-year
analysis period beginning on 1 September 2003 and ending on
31 August 2006.
Outcomes
The main outcomes prespecified in the protocol were the late
treatment effects suggested by previous studies, specifically
radiotherapy and chemotherapy effects in breast cancer (hypo-
thyroidism, heart failure, coronary artery disease, lymphoedema;
Paskett and Stark, 2000; Bradbury et al, 2005; Darby et al, 2005;
Carver et al, 2007; Smith et al, 2008) and in prostate and colorectal
cancers (erectile dysfunction, incontinence), chemotherapy effects
in colorectal cancer (dementia; Heflin et al, 2005) and hormonal
effects in breast (osteoporosis) and prostate (osteoporosis and
Table 1 Examples of potential long-term and late effects of treatment amongst breast, colorectal and prostate cancer survivors
Surgery Radiotherapy Chemotherapy Hormone therapy
Breast
Lymphoedema Shoulder stiffening
Lymphoedema
Hypothyroidism
Skin telangiectasia
Cardiac damage
Second malignancy
Thyroid damage
Anthracyclines Heart failure
Left ventricular (LV)
dysfunction (Hewitt
et al, 2006)
Tamoxifen Endometrial cancer
Osteopenia
Thromboembolic events
(Hewitt et al, 2006)
Cyclophosphamide Heart failure
Pericarditis
Premature menopause
(Hewitt et al, 2006)
Aromatase inhibitors Bone loss (Mincey et al, 2006)
Possible increased risk
of artherosclerosis
(Senkus and Jassem, 2011)
Trastuzumab Heart failure
LV dysfunction
(Hewitt et al, 2006)
Bevacizumab Hypertension
Thromoembolic events
Heart failure
(Choueiri et al, 2011)
General effects Weight gain
Cognitive dysfunction
(Partridge et al, 2001)
Prostate
Urinary incontinence
Sexual dysfunction
Pelvic fibrosis
Bowel fibrosis
Bladder/bowel
telangiectasia
Rarely used LHRH analogues Coronary artery
disease (Saigal et al, 2007)
Myocardial infarction
(Taylor et al, 2009)
Osteoporosis (Lopez et al,
2005; Taylor et al, 2009)
Mild obesity (Hewitt et al,
2006)
Sexual dysfunction
(Schover, 2005)
Bicalutamide Breast enlargement
(Hewitt et al, 2006)
Colorectal
Stoma
Bowel and urinary
incontinence
Sexual dysfunction
Pelvic necrosis
Hip osteoporosis
Bevacizumab Hypertension
Thromoembolic events
Heart failure
(Hewitt et al, 2006)
5-Fluorouracil Cardiac ischaemia
(Keefe et al, 1993)
Oxaliplatin Peripheral neuropathy
(Hewitt et al, 2006)
General effects Cognitive dysfunction
(Heflin et al, 2005)
Abbreviation: LHRH¼lutenizing hormone-releasing hormone.
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Saad et al, 2008; Taylor et al, 2009). We also prespecified diabetes
mellitus as an outcome because of its reported association with
colorectal cancer (Larsson et al, 2005; Keating et al, 2006). We also
considered long-term effects of treatment specific to each cancer,
including lymphoedema (breast cancer), early menopause (breast
cancer), non-infectious diarrhoea or constipation (colorectal
cancer), erectile dysfunction (male colorectal and prostate cancer)
and urinary incontinence (colorectal and prostate cancer). We
focussed on outcomes that we could investigate within the GPRD
by identifying incident events through Read or OXMIS codes
for the clinical diagnosis, with the exception of osteoporosis – for
which patients prescribed a bisphosphonate were included even if
they did not have a clinical code for osteoporosis or osteoporotic
fracture – and erectile dysfunction – for which we included new
prescriptions for sildenafil (Viagra, Pfizer, NY, United States),
apomorphone hydrochloride, vardenafil (Levitra, Bayer Healthcare
Pharmaceuticals, New Haven, USA), alprostadil (an injectable
treatment) and tadalafil (Cialis, Lilly, USA). Early menopause was
defined as a clinical code for menopause or early menopause in the
patient’s electronic medical record before the age of 48 years.
Clinical code lists are available on request. Only new diagnoses
were included (i.e., diagnoses that were not present in the medical
record before the cancer diagnosis) in any analyses of disease
incidence.
Statistical analyses
We calculated the incidence rate for each outcome based on the
number of events and cumulative person-years for each group of
cancer survivors and controls within the analysis period. We used
multivariate Cox proportional hazard models, stratifying for the
matched groups, to compute hazard ratios (HRs) and 95%
confidence intervals (95% CIs). This method allowed us to compare
the incidence rates for matched groups of cancer survivors and
controls. We only considered incidence of new diagnoses, and
therefore excluded any patients with a previous diagnosis of the
condition of interest before the start of the analysis period. To
formally test the proportional hazards model assumption that the
HR is proportional over time, we conducted post-estimation tests
of the correlations between Schoenfeld residuals from each
multivariate model and time (Cleves et al, 2006). In addition to
incidence within the analysis period, we also report total prevalence
from date of cancer diagnosis in the survivors and from date of
matched survivor in the control population. All analyses were
carried out using the Stata MP statistical software, version 10.1
(StataCorp LP, College Station, TX, USA).
Explanatory variables
To reduce confounding, we adjusted for smoking status and BMI
in case–control comparisons of the incidence of heart failure,
dementia, coronary artery disease, osteoporosis, diabetes and
erectile dysfunction (Kanis et al, 2005). Recording of smoking
status is high in the GPRD; however, data on former smoking
status are lower than expected (Lewis et al, 2004). Smokers may be
alternatively coded as ex, former or current smokers. Therefore, we
classified individuals as ever smokers or never smokers. In
addition, each patient was assigned a summary comorbidity score
based on the Charlson index. This weighted and additive
comorbidity score consists of 17 diagnostic categories and
accounts for both the number and severity of comorbidity to
provide a summary of disease burden for individual patients
(Charlson et al, 1987). It has been adapted for use within the GPRD
(Khan et al, 2010b).
Data on patient characteristics such as BMI and smoking status
were not complete within the GPRD; however, coverage was high
(Table 2). We compared three different approaches to dealing with
the missing data in multivariate Cox proportional hazard models:
multiple imputation, complete case analysis and use of a ‘missing’
category. As results for all three approaches were similar, we report
the results from the complete case analysis.
RESULTS
Patient characteristics
Table 2 reports the age, gender, time since diagnosis and
comorbidity score of 26213 long-term survivors of breast, colorectal
and prostate cancer and a matched control population of 104486.
The cohort was fairly elderly, and a high proportion of the
population had at least one comorbid disease. It also shows that
two of the most important confounding factors (smoking and BMI)
were in fact very similar in prevalence among all survivors and
controls, despite previous research showing a positive association
between obesity and risk of cancer (Bianchini and Vainio, 2002).
Breast cancer survivors
Incidence rates and risk of new diagnoses related to late effects of
treatment among breast cancer survivors and controls are shown
in Table 3. Long-term survivors of breast cancer had an incident
rate for heart failure of 5.73 per 1000 person-years compared with
4.40 in controls. This excess persisted in matched, multivariate
models (adjusted HR 1.95, 95% CI 1.27–3.01). In addition, breast
cancer survivors had a significantly elevated incidence of
osteoporosis compared with controls (adjusted HR 1.26, 95% CI
1.13–1.40). We included use of bisphosphonates as indicative of a
diagnosis of osteoporosis; however, some breast cancer survivors
may be receiving prophylactic bisphosphonate treatment to
prevent osteoporosis. To assess whether our case definition was
affecting these results, we conducted a sensitivity analysis after
excluding women receiving bisphosphonates from the analysis.
The risk of developing a new diagnosis of osteoporosis was broadly
similar (adjusted HR 1.38, 95% CI 1.19–1.60). A total of 260 breast
cancer survivors were clinically coded with lymphoedema, which
corresponded to an incidence rate of 6.73 per 1000 person-years
(95% CI 5.95–7.59) and a substantially elevated rate of disease
compared with controls (HR 18.12, 95% CI 13.6–24.1). There was
evidence for a slight increase in the risk of early menopause among
breast cancer survivors (adjusted HR 1.25, 95% CI 1.06–1.48).
Coronary artery disease and hypothyroidism crude incidence
rates were similar in breast cancer survivors and controls. After
accounting for matched groups and additional covariates, there
was evidence for an increased rate of coronary artery disease
(adjusted HR 1.27, 95% CI 1.11–1.44) and a marginal increase in
the risk of hypothyroidism (adjusted HR 1.26, 95% CI 1.02–1.56)
in breast cancer survivors. Coronary artery disease can affect heart
muscle function, and ultimately is a leading cause of heart failure;
however, because we have treated each outcome separately in the
analysis, this causal effect is unlikely to affect the estimates for
heart failure. Nevertheless, we compared the risk of heart failure
among breast cancer survivors who only had a clinical code for
heart failure (137 new diagnoses, HR 3.44, 95% CI 2.86–4.02) and
among breast cancer survivors with a clinical code for CAD and
heart failure (91 new diagnoses, HR 2.29, 95% CI 1.82–2.76).
Colorectal cancer survivors
Incidence rates of new diagnoses associated with surviving
colorectal cancer are shown in Table 4. There was evidence for
an increase in the incidence of dementia in colorectal cancer
survivors compared with controls (adjusted HR 1.68, 95% CI
1.20–2.35) after adjusting for BMI and Charlson score. In addition,
there was an increase of new diagnoses of diabetes among
colorectal cancer survivors, and this risk remained after adjusting
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Colorectal cancer survivors also had a significantly higher
incidence of osteoporosis (adjusted HR 1.41, 95% CI 1.15–1.73).
Incidence, prevalence and risk of long-term effects including
erectile dysfunction (adjusted HR 1.39, 95% CI 1.08–1.77), urinary
incontinence (HR 1.79, 95% CI 1.40–2.30) and bowel dysfunction
(HR 1.43, 95% CI 1.26–1.63) were significantly elevated in
colorectal cancer survivors post diagnosis.
Prostate cancer survivors
Table 5 shows the incidence and risk of new diagnoses among
prostate cancer survivors and controls. Prostate cancer survivors
had a large increase in the rate of osteoporosis compared with
matched controls (adjusted HR 2.49, 95% CI 1.93–3.22). Similar to
the breast cancer analysis, we excluded men receiving bispho-
sphonates from the case definition for osteoporosis. The results
were broadly similar (adjusted HR is 1.92, 95% CI 1.35–2.72). There
were no differences in the incidence rate of heart failure or coronary
artery disease between prostate cancer survivors and controls.
Although the multivariate analysis showed no difference in the risk
of developing erectile dysfunction among prostate cancer survivors,
the incidence rate of erectile dysfunction was significantly higher
among the prostate cancer group (23.5 new diagnoses per 1000
person-years, 95% CI 20.2–27.2). Prostate cancer survivors were
significantly more likely to experience urinary incontinence, with a
significantly higher total prevalence (Table 6) and long-term risk of
new events (HR 3.20, 95% CI 2.45–4.16).
Total prevalence
In addition to new diagnoses during the analysis period, we also
considered total prevalence of the long-term effects, including
urinary incontinence, erectile dysfunction and bowel dysfunction
(Table 6). The number of cancer survivors with a clinical record
for these long-term effects significantly increased compared with
the control population, and for the most part corresponded to the
relative risks reported in the proportional hazards models with the
exception of erectile dysfunction, which was recorded in almost
twice as many prostate cancer survivors as controls.
DISCUSSION
Statement of principal findings
This large population-based matched cohort study has described the
incidence and risk of new diagnoses related to late effects of treatment
in long-term survivors of breast, colorectal and prostate cancer. We
have confirmed previously reported associations between breast
cancer and heart failure, coronary artery disease and hypothyroidism,
and the increased risk of osteoporosis in all three cancers. We did not
confirm the increase of coronary artery disease in prostate cancer;
however, this analysis did show an association between colorectal
cancer and diabetes mellitus, with an increased incidence of almost
four new cases of diabetes per 1000 person-years. The incidence rate
for osteoporosis was comparable between all cancer groups. Despite
these associations, the absolute rise in incidence is very modest in this
general population, with the exception of osteoporosis and urinary
incontinence among prostate cancer survivors.
Comparison with other research
This is the first UK-based study to report the incidence and risk of
new diagnoses related to late effects of treatment in an unselected
population of cancer survivors. The study confirms most of the
Table 2 Characteristics of cancer survivors and matched controls (four patients of the same age and gender from the same primary care practice without
a diagnosis of cancer) by cancer type
Breast Colorectal Prostate
Survivor Control Survivor Control Survivor Control
Gender
Male — — 2569 10178 4207 16709
Female 16938 67649 2499 9950 — —
Mean age
a (in years) 66.9 74.1 76.1
Standard deviation 12.3 10.9 8.1
Mean years from diagnosis
a 10.2 — 10.1 — 5.8 —
Standard deviation 7.5 — 7.9 — 3.6 —
Charlson comorbidity score40 7551 27999 2942 10343 2693 9345
% 44.6% 41.4% 58.1% 51.4% 64.0% 55.9%
Smoking status
Ever smoked 5738 23188 2238 8428 2139 9012
% 33.9% 34.3% 44.1% 41.9% 50.8% 53.9%
Never smoked 10703 42452 2662 10889 1968 7044
% 63.2% 62.8% 52.5% 54.1% 46.8% 42.2%
BMI
Underweight 583 2264 160 616 77 359
% 3.9% 3.8% 3.7% 3.6% 2.1% 2.5%
Normal weight 6046 23651 1618 6654 1380 5651
% 41.2% 39.8% 37.8% 38.9% 37.3% 39.1%
Overweight 5030 20169 1695 6781 1625 6355
% 34.3% 33.9% 39.6% 39.7% 43.9% 43.9%
Obese 3023 13296 804 3033 623 2105
% 20.6% 22.4% 18.8% 17.8% 16.8% 14.6%
aThe date used to calculate years from cancer diagnosis was 1 September 2003, and the year used to calculate age was 2003.
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Incidence Hazard ratio
a
n
Incidence rate per
1000 person-years 95% CI Unadjusted 95% CI Adjusted 95% CI
Heart failure
Cancer survivors 228 5.73 5.0–6.5 1.80 1.51–2.13 1.95 1.27–3.01
Controls without cancer 760 4.40 4.1–4.7 —
Coronary artery disease
Cancer survivors 410 10.86 9.9–12.0 1.29 1.14–1.45 1.27 1.11–1.44
Controls without cancer 1726 10.60 10.1–11.1 —
Dementia
Cancer survivors 211 5.19 4.54–5.94 1.62 1.36–1.93 1.21 0.95–1.53
Controls without cancer 800 4.52 4.22–4.85
Hypothyroidism
Cancer survivors 437 11.76 10.7–12.9 1.18 1.05–1.32 1.26 1.02–1.56
Controls without cancer 1772 10.95 10.5–11.5 —
Osteoporosis
Cancer survivors 656 18.07 16.7–19.5 1.40 1.28–1.54 1.26 1.13–1.40
Controls without cancer 2305 14.57 13.9–15.2 —
Lymphoedema
Cancer survivors 260 6.73 5.95–7.59 18.12 13.6–24.1 — —
Controls without cancer 77 0.34 0.34–0.54
Early menopause
b
Cancer survivors 186 4.51 3.91–5.21 1.25 1.06–1.48 1.25 1.06–1.48
Controls without cancer 664 3.72 3.45–4.02
Abbreviation: CI¼confidence interval.
aThe hazard ratio in each case is based on individual comparison with controls matched for age, gender and primary care practice (i.e., the
comparison for patients treated with radiotherapy is with controls individually matched to patients receiving radiotherapy rather than all controls); the adjusted hazard ratio takes
account of the potential confounding effect of smoking and BMI (except for hypothyroidism which is adjusted for BMI and history of hormone therapy only, and early menopause
which is adjusted for smoking only).
bDefined as menopause before the age of 48 years.
Table 4 Incidence of new diagnoses related to treatment among colorectal cancer survivors
Incidence Hazard ratio
a
n
Incidence rate per
1000 person-years 95% CI Unadjusted 95% CI Adjusted 95% CI
Dementia
Cancer survivors 116 10.08 8.4–12.1 2.10 1.65–2.68 1.68 1.20–2.35
Controls without cancer 356 7.02 6.3–7.8 —
Osteoporosis
Cancer survivors 190 18.02 15.6–20.8 1.60 1.35–1.91 1.41 1.15–1.73
Controls without cancer 597 12.86 11.9–13.9 —
Diabetes
Cancer survivors 176 17.01 14.7–19.7 1.40 1.15–1.70 1.39 1.12–1.72
Controls without cancer 616 13.21 12.2–14.3 —
Erectile dysfunction
Cancer survivors 118 23.00 19.2–27.5 1.42 1.11–1.81 1.39 1.08–1.77
Controls without cancer 392 16.55 14.9–18.3
Urinary incontinence
Cancer survivors 252 14.49 12.8–16.4 1.79 1.40–2.30
Controls without cancer 853 12.09 11.3–12.9
Diarrhoea or constipation
Cancer survivors 441 67.99 61.9–74.6 1.43 1.26–1.63
Controls without cancer 1939 51.68 49.4–54.0
Abbreviation: CI¼confidence interval.
aThe hazard ratio in each case is based on individual comparison with controls matched for age, gender and primary care practice; the
adjusted hazard ratio takes account of the potential confounding effect of comorbidity, BMI (and for osteoporosis and erectile dysfunction also for smoking).
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from cross-sectional studies and specialist databases. The risk of
heart failure, hypothyroidism and osteoporosis among breast
cancer survivors in this cohort was similar to previously reported
research (Mincey et al, 2006; Pinder et al, 2007; Smith et al, 2008).
However, rates of osteoporosis among prostate cancer survivors in
this cohort were substantially higher compared with the results
from a meta-analysis assessing the risk of androgen deprivation
therapy-related osteoporosis (Taylor et al, 2009). We did not
identify any non-reported outcomes from this study. Low-level
incontinence can develop in some patients many years after radical
prostatectomy. Previous research on the incidence of pelvic late
effects has documented a substantial increase in the risk of bowel
and urinary incontinence, which was mirrored in this cohort where
the incidence of long-term effects such as urinary incontinence,
erectile dysfunction and bowel dysfunction was substantially
higher among the cancer survivors in this population (Farnell
et al, 2010; Henson et al, 2011). These may affect cancer survivors
closer to diagnosis; however, we did not have longitudinal follow-
up data on this cohort before 2 years post diagnosis (Chen et al,
2009).
Strengths and limitations
This analysis uses data from a large, representative database, and
quantified new diagnoses in a community-based group of cancer
survivors with a robust comparison population. Although large
data repositories such as the GPRD offer the opportunity to access
information on a large number of patients, there are several
limitations inherent to conducting research in a data set that has
not been collected primarily for research purposes. The main
drawback of this observational research is that it is not possible to
explore the relationships between specific treatments and new
diagnoses. A lack of detailed treatment information from the
GPRD prevented analysis of treatment effects among the entire
cohort. We attempted to gain additional treatment data by linking
this GPRD data set with National Cancer Intelligence Network
(NCIN); however, historical treatment data have not been
consistently recorded across the different national cancer regis-
tries. A summary of treatment data that was available for this study
is shown in Appendix. There is a strong need for improvements
in capturing cancer treatment at cancer registries, and more
importantly cancer treatment data need to be incorporated into
patient electronic medical records in primary care. Read coding of
radiotherapy, chemotherapy and surgery is weak in primary care,
which needs to improve before general practitioners (GPs) can
identify individual cancer treatment histories and assess risk for
late effects among long-term cancer survivors. In addition, because
Table 5 Incidence of new diagnoses related to treatment amongst prostate cancer survivors
Incidence Hazard ratio
a
n
Incidence rate per
1000 person-years 95% CI Unadjusted 95% CI Adjusted 95% CI
Heart failure
Cancer survivors 129 17.1 14.4–20.3 1.66 1.32–2.10 1.23 0.91–1.66
Controls without cancer 486 13.8 12.6–15.1 —
Coronary artery disease
Cancer survivors 173 27.95 24.1–32.4 1.27 1.05–1.56 1.17 0.94–1.46
Controls without cancer 863 29.15 27.3–31.2 —
Osteoporosis
Cancer survivors 120 15.38 12.9–18.4 2.39 1.89–3.00 2.49 1.93–3.22
Controls without cancer 292 7.98 7.1–8.9 —
Erectile dysfunction
Cancer survivors 163 23.51 20.2–27.4 1.22 0.96–1.55 1.17 0.91–1.49
Controls without cancer 563 16.13 14.8–17.5
Urinary incontinence
Cancer survivors 315 20.43 18.3–22.8 3.20 2.45–4.16
Controls without cancer 677 12.45 11.5–13.4
Abbreviation: CI¼confidence interval.
aThe hazard ratio in each case is based on individual comparison with controls matched for age, gender and primary care practice (i.e. the
comparison for patients treated with radiotherapy is with controls individually matched to patients receiving radiotherapy rather than all controls); the adjusted hazard ratio takes
account of the potential confounding effect of comorbidity, smoking and BMI.
Table 6 Total prevalence of long-term effects in cancer survivors and
controls
Number
of events
No
event
Total
patients
Urinary incontinence
Prostate
Survivor 411 (9.8%)
a 3796 (90.2%) 4207
Control 525 (3.1%) 16184 (96.9%) 16709
Colorectal
Survivor 324 (6.4%)
a 4744 (93.6%) 5068
Control 1022 (5.1%) 19106 (94.9%) 20128
Erectile dysfunction
Prostate
Survivor 662 (15.7%)
a 3545 (84.3%) 4207
Control 1394 (8.3%) 15315 (91.7%) 16709
Colorectal (men only)
Survivor 344 (13.4%)
a 2225 (86.6%) 2569
Control 931 (9.2%) 9247 (90.8%) 10178
Diarrhoea or constipation
Colorectal
Survivor 2300 (45.4%)
a 2768 (54.6%) 5068
Control 5792 (28.8%) 14336 (71.2%) 20128
aSignificant at P o0.0001 in Pearson’s X
2-comparisons.
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proportion of potentially confounding baseline patient character-
istics into account.
The results need to be interpreted with caution, as the
mechanisms underlying these new diagnoses have not been fully
elucidated, disease definitions are not standardised in the GPRD
and incident diseases may result from shared risk factors with the
initial cancer (Wefel and Meyers, 2005). Although conducting a
comparison between cancer survivors and a control population
minimises bias due to misclassification or failure to record clinical
data, it is possible that the raised risks of disease are partly due
to increased follow-up and clinical contact among the cancer
survivors group. In addition, we have conducted numerous
statistical tests, but have not adjusted for multiple comparisons.
Case definition is an important issue to consider when using
administrative databases for research purposes (Khan et al, 2010a).
Previous validation studies of the GPRD have suggested that
prescribing data can be used to capture additional cases when the
prescribed drug is specific to the diagnosis of interest (Hansell et al,
1999). Accordingly, we included bisphosphonates in the case
definition for osteoporosis among the cancer survivors and control
population, which was supported by sensitivity analyses. Use of
prophylactic bisphosphonates for prevention of osteoporosis is not
currently recommended among cancer survivors receiving aroma-
tase inhibitors; however, it is possible that this may occur in practice.
It is also possible that prostate cancer survivors receiving bispho-
sphonates as treatment for skeletal metastases were wrongly
attributed as osteoporotic. It is a potential limitation of these
analyses that it has not been possible to specifically identify those
patients with secondary disease; however, only 14 of the 120 prostate
cancer survivors who were identified as osteoporotic solely on the
basis of a new prescription of a bisphosphonate had a PSA level
suggestive of secondary disease (defined as at least one PSA reading
over 50ngml
 1), which suggests that misclassification bias is
minimal in this instance. Furthermore, results of a sensitivity
analysis excluding those patients receiving bisphosphonates show
broadly similar relative results for risk of osteoporosis among cancer
survivors compared with matched controls.
Implications of the study
Although this study has shown that long-term cancer survivors are
a population at risk, the absolute increase in disease burden is
small apart from the risk of osteoporosis. Most cancer survivors
readjust to their disease and do not have long-term physical or
psychological sequelae. These findings support the approach of the
UK National Cancer Survivors Initiative to develop risk stratifica-
tion tools to manage cancer survivors post treatment (National
Cancer Survivorship (NSCI) Research Workstream, 2010). Most
of these patients will be cared for in primary care, and GPs will
need an awareness of the increased risks in individual patients.
Our findings certainly suggest a substantially increased risk of
osteoporosis among prostate cancer survivors, and adequate
surveillance systems are required to manage this risk. Guidelines
developed by the National Institute for Health and Clinical
Excellence recommend baseline dual energy X-ray absorptiometry
scans to women with breast cancer; however, no current guidelines
exist for the management of bone loss among prostate cancer
survivors (National Collaborating Centre for Cancer, 2009).
General practitioners will also need to pay special attention to
the presence of risk factors in this population that may have led to
the original cancer diagnosis, as well as managing long-term
treatment effects.
Although large, prospective cohort studies have described late
effects among childhood cancer survivors (Oeffinger et al, 2006;
Reulen et al, 2007), there is a strong need for similar work among
survivors of adult cancer. In order to better elucidate the
relationships between treatment and late effects, future research
needs to involve detailed and individual-level treatment data; this
will allow an assessment of risk stratified by treatment. This may
involve further research using existing databases, as recording
of treatment improves within cancer registries and primary care,
or long-term follow-up of participants of treatment clinical trials
where detailed information on treatment and individual-level
patient characteristics will have been collected at baseline.
Conclusion
This research has confirmed the increased incidence of previously
reported late effects of treatment in long-term survivors of cancer
in an unselected population. Although the absolute increase of
most late effects is small, clinicians will need an awareness of these
risks.
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Treatment data available in GPRD-NCIN-linked database
Yes No Total % Of total patients
Radiotherapy
Breast 4509 2539 7048 41.6
Colorectal 322 1111 1433 28.3
Prostate 717 974 1691 40.2
Total 5548 4624 10172 38.8
Chemotherapy
Breast 2677 3352 6029 35.6
Colorectal 684 1010 1694 33.4
Prostate 171 1187 1358 32.3
Total 3532 5549 9081 34.6
Surgery
Breast 4980 1574 6554 38.7
Colorectal 1421 501 1922 37.9
Prostate 1053 812 1865 44.3
Total 7454 2887 10341 39.4
Hormone therapy
Breast 13304 716 14020 82.8
Colorectal 231 1214 1445 28.5
Prostate 3197 369 3566 84.8
Total 16732 2299 19031 72.6
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